Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples